Dara Tahereh, Zabihi Mohsen, Hoseinzade Farahnaz, Rohani Mahyar, Saghafi Fatemeh
Department of Pharmaceutics, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Department of Pharmacology, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Cardiovasc Diabetol Endocrinol Rep. 2025 May 26;11(1):10. doi: 10.1186/s40842-025-00222-y.
Type 2 diabetes mellitus is a chronic condition driven by insulin resistance and impaired beta-cell function. As beta cells gradually lose function, blood glucose levels rise, leading to clinical diabetes. This condition also elevates the risk of cardiovascular complications. Treatment typically requires multiple medications with different mechanisms of action. Recent developments include bromocriptine, a dopamine agonist approved by the Food and Drug Administration (FDA) for type 2 diabetes, which has been shown to reduce plasma glucose, triglycerides, and free fatty acid levels. To deepen our understanding of type 2 diabetes and refine treatment approaches, a comprehensive analysis of clinical studies and related data is essential.
This systematic review and meta-analysis investigated the efficacy of bromocriptine in diabetes outcomes by analyzing randomized clinical trials (RCTs) in English up to November 25, 2024. The comprehensive search spanned Scopus, PubMed, and Web of Science, with additional studies identified through supplementary web searches and reference list checks. Inclusion criteria required clinical trials with clear methodologies and defined drug dosages. Data extraction gathered information on study design, outcomes, and intervention specifics, with quality assessment using the JADAD scoring system. Statistical analysis focused on standard mean difference (SMD), while the I statistic measured study heterogeneity. A funnel plot analysis was employed to identify publication bias, with all analyses conducted using Comprehensive Meta-Analysis and Stata software.
Eighteen RCTs were conducted, revealing that dopamine D2 agonists have a relatively strong impact on reducing Hemoglobin A1C (HbA1c) and fasting blood sugar (FBS). However, with I values of 96% for HbA1c and 99% for FBS, the results show high heterogeneity among the studies.
Bromocriptine presents a promising alternative for individuals with diabetes who cannot tolerate conventional medications. Its unique mechanism of action might offer relief to those who suffer from side effects associated with standard treatments, providing a novel way to manage blood sugar levels.
2型糖尿病是一种由胰岛素抵抗和β细胞功能受损驱动的慢性疾病。随着β细胞功能逐渐丧失，血糖水平升高，导致临床糖尿病。这种情况还会增加心血管并发症的风险。治疗通常需要多种作用机制不同的药物。最近的进展包括溴隐亭，一种被美国食品药品监督管理局（FDA）批准用于2型糖尿病的多巴胺激动剂，已被证明可降低血浆葡萄糖、甘油三酯和游离脂肪酸水平。为了加深我们对2型糖尿病的理解并完善治疗方法，对临床研究和相关数据进行全面分析至关重要。
本系统评价和荟萃分析通过分析截至2024年11月25日的英文随机临床试验（RCT）来研究溴隐亭在糖尿病结局方面的疗效。全面检索涵盖了Scopus、PubMed和科学网，通过补充网络搜索和参考文献列表检查确定了其他研究。纳入标准要求临床试验具有明确的方法和确定的药物剂量。数据提取收集了有关研究设计、结局和干预细节的信息，并使用JADAD评分系统进行质量评估。统计分析侧重于标准平均差（SMD），而I统计量衡量研究异质性。采用漏斗图分析来识别发表偏倚，所有分析均使用综合荟萃分析和Stata软件进行。
共进行了18项RCT，结果显示多巴胺D2激动剂对降低糖化血红蛋白（HbA1c）和空腹血糖（FBS）有相对较强的影响。然而，HbA1c的I值为96%，FBS的I值为99%，结果显示研究之间存在高度异质性。
对于无法耐受传统药物的糖尿病患者，溴隐亭是一种有前景的替代药物。其独特的作用机制可能为那些遭受标准治疗相关副作用的患者提供缓解，为控制血糖水平提供一种新方法。
Zotero 插件